Last Updated: August 15, 2026

CLINICAL TRIALS PROFILE FOR CBP-307

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for CBP-307

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02280434 ↗	Phase 1 Study Accessing the Safety and Tolerability of CBP-307	Completed	Nucleus Network Ltd	Phase 1	This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
NCT02280434 ↗	Phase 1 Study Accessing the Safety and Tolerability of CBP-307	Completed	Tigermed Consulting Co., Ltd	Phase 1	This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
NCT02280434 ↗	Phase 1 Study Accessing the Safety and Tolerability of CBP-307	Completed	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 1	This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
NCT04700449 ↗	A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)	Recruiting	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 2	This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
NCT04818229 ↗	A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects	Recruiting	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 1	This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
NCT05040113 ↗	A Study On Human Mass Balance And Biotransformation	Recruiting	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 1	This study will evaluate the absorption,metabolism and excretion of CBP-307 in healthy chinese male subjects.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for CBP-307

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Autoimmune Diseases	2
Healthy Adult Subjects	1
Moderate to Severe Ulcerative Colitis	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Autoimmune Diseases	2
Ulcer	1
Colitis, Ulcerative	1
Colitis	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CBP-307

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	19
United States	8
Australia	2
Ukraine	1
Pakistan	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Georgia	1
Florida	1
California	1
Arizona	1
Texas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CBP-307

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CBP-307

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Suzhou Connect Biopharmaceuticals, Ltd.	4
Nucleus Network Ltd	1
Tigermed Consulting Co., Ltd	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	5
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.